DNA Vaccine For C. Difficile
Patients who get infected by C. difficile often develop serious complications such as severe diarrhoea, bowel perforation, toxic megacolon, multi-organ failure and even death. In most cases, the onset of disease symptoms from C. difficile occurs within ten to fourteen days.
Half a million C. difficile infections occur annually in the US and the cost of fighting these infections is approximately $10 billion a year. Both morbidity and mortality associated with this bacterium have been increasing over the last decade. It is thus important to develop a prophylactic treatment that can prevent the toxin-mediated cytopathology. A short vaccination regimen that could boost through either immunisation or natural infection would be ideal to prevent the onset of CDAD in high-risk patients.
Treatment of disease by C. difficile infections is especially difficult since the bacterial spores persist in the hospital environment. Most infections occur in such a setting. Moreover, since there is no standard or effective treatment for recurrent disease, there is a definite need to develop an improved therapy.
This particular research experiment was conducted with mice and non-human primates. The animal models were immunised intramuscularly followed by in vivo electroporation. The results indicated that the vaccine successfully protected the animals against the purified toxins of C.difficile. The animals were also protected from an orogastric spore infection, a laboratory model that mimicked the human disease. This protection was achieved after only two immunisations.
According to Michele Kutzler, a corresponding author from the Druxel University College of Medicine, Philadelphia, "Animals that received two immunisations did not get sick or show signs of C. difficile-associated disease."
This study demonstrates that once fully developed, this vaccine has the potential to prevent these effects and protect patients from the consequences of C. difficile.
The new vaccine works against C.difficile by mustering anti-toxin neutralizing antibodies. During this study, it was shown to be safe and effective after only two immunisations. The overall performance of the vaccine was excellent and the positive results indicate that further studies should be conducted with human patients to study the vaccine further as it could play an important role in the prevention and treatment of C.difficile associated disease.
Source: American Society for Microbiology
Image Credit: Wikimedia Commons
Published on : Tue, 5 Aug 2014
Print as PDF
XENIOS AG is a medical device company with the three brands, novalung, i-cor and medos, that run on a single XENIOS platform. This platform enables next-generation therapies for lung and heart failure. No other company except XENIOS AG is offering lung...
Features The SynoVent E3 does not only include advanced ventilator functionality but also a modern, easy to use interface. The display can be configured to suit each clinician’s taste and needs, and gives quick and easy control over ventilator parameters...
The fully featured ICU ventilator, HAMILTON-MR1, guarantees uncompromised continuous ventilation care from the ICU to the MRI scanner and back. Its reliability and high performance, with advanced lung-protective strategies and patient-adaptive modes,...
The HAMILTON-C6 represents a new Generation of high-end ventilators. The combination of modularity, ease of use, mobility, and advanced features allows you to individualize your patient's ventilation therapy: - State-of-the-art ventilation modes for adult,...
Features The SynoVent E5 is the ventilator you need with the interface you want. It does not only include advanced ventilator functionality for patients ranging from infant to adult, but also a modern, easy-to-use interface. The display can be configured...